Impact of mechanism-based enzyme inactivation on inhibitor potency: Implications for rational drug discovery

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Scopus

• Publication date

  2000-11-01

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1002/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Inactivation of nitric oxide synthase by substituted aminoguanidines and aminoisothioureas.

  1997cited by this paper
• Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.

  1997cited by this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cited by this paper
• BENEFICIAL VERSUS DETRIMENTAL EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITORS IN CIRCULATORY SHOCK LESSONS LEARNED FROM EXPERIMENTAL AND CLINICAL STUDIES

  1997cited by this paper
• Inhibition of nitric oxide synthase with pyrazole-1-carboxamidine and related compounds.

  1997cited by this paper
• Inactivation and recovery of nitric oxide synthetic capability in cytokine-induced RAW 264.7 cells treated with "irreversible" NO synthase inhibitors.

  1997cited by this paper
• 1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo*

  1997cited by this paper
• Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform

  1996cited by this paper
• Suppression of rat hepatic cytochrome P450 2E1 expression by isopropyl 2-(1,3-dithioetane-2-ylidene)-2-[N-(4-methyl-thiazol-2-yl)carbamoyl] acetate (YH439), an experimental hepatoprotectant: protective role against hepatic injury.

  1996cited by this paper
• Selective pharmacological inhibition of distinct nitric oxide synthase isoforms.

  1996cited by this paper
• Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine.

  1996cited by this paper
• N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases.

  1995cited by this paper
• Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity

  1995cited by this paper
• "Suicide" inactivation of prostaglandin I2 synthase: characterization of mechanism-based inactivation with isolated enzyme and endothelial cells.

  1995cited by this paper
• Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.

  1995cited by this paper
• Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase.

  1995cited by this paper
• Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

  1994cited by this paper
• L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.

  1994cited by this paper
• Approaches toward selective inhibition of nitric oxide synthase.

  1994cited by this paper
• Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.

  1994cited by this paper
• Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine.

  1993cited by this paper
• The first mechanism-based inactivators for angiotensin-converting enzyme.

  1992cited by this paper
• Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin

  1992cited by this paper
• Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors.

  1992cited by this paper
• Endothelial nitric oxide generating enzyme(s) in the bovine aorta: subcellular location and metabolic characterization.

  1990cited by this paper
• Oxidation of cycloalkylamines by cytochrome P-450. Mechanism-based inactivation, adduct formation, ring expansion, and nitrone formation.

  1989cited by this paper
• The theophylline-erythromycin interaction.

  1988cited by this paper
• The potential use of mechanism-based enzyme inactivators in medicine.

  1988cited by this paper
• Disruption of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P‐450

  1988cited by this paper
• Enzyme-activated/mechanism-based inhibitors.

  1987cited by this paper
• Drug interactions with macrolide antibiotics: specificity of pseudo-suicide inhibition and induction of cytochrome P-450.

  1986cited by this paper
• Mechanism-based enzyme inactivators.

  1984cited by this paper
• [3] Mechanism-based irreversible enzyme inhibitors

  1977cited by this paper
• Chemistry and enzymology of kcat inhibitors.

  1974cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Interactions of Linalool and Linalyl Acetate with Selected Dog Cytochrome P450 (CYP) Proteins Identified by In Silico Drug Discovery Followed by Molecular Docking Analysis

  2025cites this paper
• Covalent ligand efficiency.

  2025cites this paper
• Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors.

  2024cites this paper
• Covalent Hits and Where to Find Them.

  2024cites this paper
• Quantitative Measurements of Pharmacological and Toxicological Activity of Molecules

  2022cites this paper
• The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization.

  2020cites this paper
• Evaluation of Cytochrome P450 Selectivity for Hydralazine as an Aldehyde Oxidase Inhibitor for Reaction Phenotyping.

  2019cites this paper
• Single concentration loss of activity assay provides an improved assessment of drug–drug interaction risk compared to IC50-shift

  2016cites this paper
• Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach.

  2013cites this paper
• In vitro techniques to study drug-drug interactions of drug metabolism: Cytochrome P450

  2010cites this paper
• Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance

  2010cites this paper
• In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A

  2010cites this paper
• IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4

  2010cites this paper
• Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

  2009cites this paper
• Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values

  2009cites this paper
• Progress Curve Analysis of CYP1A2 Inhibition: A More Informative Approach to the Assessment of Mechanism-Based Inactivation?

  2007cites this paper
• Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes

  2005cites this paper
• Drug Metabolism In Preclinical Development

  2004cites this paper
• Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.

  2003cites this paper